netFormulary
 Report : Medicines with links to NICE 03/12/2020 17:06:26

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA280: Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234)
Abatacept 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abatacept 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abiraterone 08.03.04.02 Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
Adalimumab 13.05.03 Non Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 13.05.03 Non Formulary NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Adalimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adefovir Dipivoxil 05.03.03 Non Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adefovir Dipivoxil 05.03.03 Non Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Afatinib 08.01.06 Non Formulary NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
Aflibercept 08.01.06 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 08.01.06 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 08.01.06 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Aflibercept 08.01.06 Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 08.01.06 Formulary NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 11.08.02 Non Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Non Formulary NICE TA294: Macular degeneration (wet age-related) - aflibercept
Alemtuzumab 08.02.03 Non Formulary NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alendronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Alitretinoin 13.05.01 Non Formulary NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Non Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apixaban 02.08.02 Formulary NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Aripiprazole 04.02.01 Non Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Aripiprazole 04.02.01 Non Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Atezolizumab 08.01.06 Formulary NICE TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.01.06 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.01.06 Formulary NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Axitinib 08.01.06 Formulary NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azacitidine 08.01.03 Formulary NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Bendamustine 08.01.01 Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Bevacizumab 08.01.06 Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Bevacizumab 08.01.06 Formulary NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Bevacizumab 08.01.06 Formulary NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Bevacizumab 08.01.06 Formulary NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Bevacizumab 08.01.06 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.06 Formulary NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Bevacizumab 08.01.06 Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.06 Formulary NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Bevacizumab 08.01.06 Formulary NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Bivalirudin 02.08.01 Non Formulary NICE CG94: Unstable angina and NSTEMI
Bivalirudin 02.08.01 Non Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Boceprevir 05.03.03 Non Formulary NICE TA253: Hepatitis C (genotype 1) - boceprevir
Bortezomib 08.01.06 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib 08.01.06 Formulary NICE TA299: Leukaemia (chronic myeloid) - bosutinib
Bortezomib 08.01.06 Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.06 Formulary NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Bortezomib 08.01.06 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bosutinib 08.01.06 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.07.04.02 Non Formulary NICE TA260: Botox for migraine prophylaxis
Brentuximab vedotin 08.01.06 Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.06 Formulary NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Cabazitaxel 08.01.06 Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.06 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Cabozantinib 08.01.06 Formulary NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.06 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Capecitabine 08.01.03 Formulary NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Capecitabine 08.01.03 Formulary NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
Capecitabine 08.01.03 Formulary NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Capecitabine 08.01.03 Formulary NICE TA191: Capecitabine for the treatment of advanced gastric cancer
Capecitabine 08.01.03 Formulary NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Cetuximab 08.01.06 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.06 Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.06 Formulary NICE TA176: Colorectal cancer (first line) - cetuximab
Cetuximab 08.01.06 Formulary NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Cetuximab 08.01.06 Formulary NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Cetuximab 08.01.06 Formulary NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Cetuximab 08.01.06 Formulary NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Cinacalcet 09.05.01.02 Formulary NICE TA117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Cladribine 08.01.03 Formulary NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Clopidogrel 02.09 Formulary NICE TA80: Acute coronary syndromes - clopidogrel
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Crizotinib 08.01.06 Non Formulary NICE TA296: Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
Crizotinib 08.01.06 Formulary NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Crizotinib 08.01.06 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.06 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Daclatasvir 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Daratumumab 08.01.06 Formulary NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Dasabuvir 05.03.03.02 Formulary Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.06 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Dasatinib 08.01.06 Formulary NICE TA241: CML for whom treatment with imatinib has failed because of intolerance
Dasatinib 08.01.06 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.06 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Denosumab 06.06.02 Formulary NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Denosumab 06.06.02 Formulary NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Denosumab 06.06.02 Non Formulary NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone intravitreal implant 11.04.01 Non Formulary NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Dimethyl Fumarate 13.05.02 Non Formulary NICE TA474: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Docetaxel 08.01.06 Formulary NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.06 Formulary NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Docetaxel 08.01.06 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Donepezil 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Doxorubicin Hydrochloride 08.01.02 Non Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Dronedarone 02.03.02 Formulary NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation
Dupilumab 13.05.03 Non Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Edoxaban 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir with grazoprevir 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
Eltrombopag 09.01.04 Non Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Entecavir 05.03.03 Non Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Entecavir 05.03.03 Non Formulary NICE CG165: Hepatitis B (incorporates TA153)
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Eribulin 08.01.06 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Eribulin 08.01.06 Formulary NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Erlotinib 08.01.06 Non Formulary NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Erlotinib 08.01.06 Non Formulary NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Erlotinib 08.01.06 Non Formulary NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Etanercept 13.05.03 Non Formulary NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA35: Arthritis (juvenile idiopathic) - etanercept
Etanercept 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Everolimus 08.01.06 Formulary NICE TA295: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor):
Everolimus 08.01.06 Formulary NICE TA219: Everolimus for second-line treatment of renal cell cancer
Everolimus 08.01.06 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.06 Formulary NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Everolimus 08.01.06 Formulary NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.06 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.06 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exemestane 08.03.04.01 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Exenatide prolonged release 06.01.02.03 Formulary NICE TA248: MR exenatide
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Restricted Use NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout
Finasteride 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Non Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fluocinolone intravitreal implant 11.04.01 Non Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)
Fluorouracil 08.01.03 Formulary NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Fulvestrant 08.03.04.01 Formulary NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gefitinib 08.01.06 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gefitinib 08.01.06 Formulary NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Gemcitabine 08.01.03 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Gemcitabine 08.01.03 Formulary NICE TA116: Gemcitabine for the treatment of metastatic breast cancer
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Golimumab 10.01.03 Formulary NICE TA220: Psoriatic arthritis - golimumab
Golimumab 10.01.03 Formulary NICE TA233: Ankylosing spondylitis - golimumab
Golimumab 10.01.03 Formulary NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Golimumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Ibrutinib 08.01.06 Formulary NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.06 Formulary NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibrutinib 08.01.06 Formulary NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Imatinib 08.01.06 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.06 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 08.01.06 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib 08.01.06 Formulary NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Imatinib 08.01.06 Formulary NICE TA196: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
Imatinib 08.01.06 Formulary NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imatinib 08.01.06 Formulary NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Imatinib 08.01.06 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Imatinib 08.01.06 Formulary NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Infliximab 10.01.03 Non Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab 10.01.03 Non Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 01.05.03 Formulary NICE TA140: Ulcerative colitis (subacute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 13.05.03 Non Formulary NICE TA134: Infliximab for the treatment of adults with psoriasis
Infliximab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Infliximab 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Insulin 06.01.01.01 Non Formulary Nice web site
Ipilimumab 08.01.06 Non Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.06 Non Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Irinotecan Hydrochloride 08.01.06 Formulary NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Ivabradine 02.06.03 Formulary NICE TA267: Ivabradine for treating chronic heart failure
Lapatinib 08.01.06 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenvatinib 08.01.06 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lenvatinib 08.01.06 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Liraglutide 06.01.02.03 Formulary NICE TA203: Diabetes (type 2) - liraglutide
Lubiprostone 01.02 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Mannitol inhalation 20 Non Formulary NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Memantine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Mifamurtide 08.02.04 Non Formulary NICE TA235: Osteosarcoma - mifamurtide
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naloxegol 01.06.06 Formulary NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Non Formulary NICE TA115: Drug misuse - naltrexone
Natalizumab 08.02.04 Non Formulary NICE TA127: Multiple sclerosis - natalizumab
Nilotinib 08.01.06 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Nilotinib 08.01.06 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nilotinib 08.01.06 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.06 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nivolumab 08.01.05 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.01.05 Formulary NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 08.01.05 Formulary NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab 08.01.05 Formulary NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nivolumab 08.01.05 Formulary NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.01.05 Formulary NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.01.05 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Obinutuzumab 08.02.03 Formulary NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 08.02.03 Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Ocriplasmin 11.08.02 Non Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA202: Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
Ofatumumab 08.02.03 Formulary NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Omalizumab 03.04.02 Non Formulary NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
Ombitasvir with paritaprevir and ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Oseltamivir 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Oseltamivir 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Osimertinib 08.01.06 Formulary NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.06 Formulary NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Oxaliplatin 08.01.06 Formulary NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Paclitaxel 08.01.06 Formulary NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Paclitaxel 08.01.06 Formulary NICE TA108: Breast cancer (early) - paclitaxel
Paclitaxel albumin 08.01.06 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Palbociclib 08.01.06 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.06 Formulary NICE TA242: NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Panitumumab 08.01.06 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.06 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.06 Formulary NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
Pegaptanib Sodium 11.08.02 Non Formulary NICE TA155: guidance on pegaptanib in AMD (August 2008)
Peginterferon Alfa 08.02.03 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.03 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.03 Formulary NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa 08.02.03 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.03 Formulary NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pemetrexed 08.01.03 Formulary NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA309: Lung cancer (non small cell, non squamous) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma
Pemetrexed 08.01.03 Formulary NICE TA124: Pemetrexed for the treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Perampanel 04.08.01 Non Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.06 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 08.01.06 Formulary Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pertuzumab 08.01.06 Formulary Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 08.01.06 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus 13.05.03 Non Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
pirfenidone 20 Non Formulary NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Prasugrel 02.09 Restricted Use NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)
Prasugrel 02.09 Restricted Use NICE TA182: Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Formulary NICE TA211: Prucalopride for the treatment of chronic constipation in women
Raloxifene Hydrochloride 06.04.01.01 Non Formulary NICE TA160: quick reference guide on osteoporosis
Ranibizumab 11.08.02 Non Formulary NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Ranibizumab 11.08.02 Non Formulary NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
Ranibizumab 11.08.02 Non Formulary NICE TA274: Macular oedema (diabetic) - ranibizumab
Ranolazine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina
Retigabine 04.08.01 Non Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.03.02 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Ribavirin 05.03.03.02 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.03.02 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.03.02 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Rifaximin 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Non Formulary NICE TA20: Motor neurone disease - riluzole
Rituximab 08.02.03 Formulary NICE TA65: Non-Hodgkin’s lymphoma - rituximab
Rituximab 08.02.03 Formulary NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA174:Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA110: Follicular lymphoma - rituximab Non-Hodgkin's lymphoma - rituximab
Rituximab 08.02.03 Formulary NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
Rituximab 08.02.03 Formulary NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab (rheumatology) 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Rituximab (rheumatology) 10.01.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Roflumilast 03.03.03 Non Formulary NICE TA244: Chronic obstructive pulmonary disease - roflumilast
Romiplostim 09.01.04 Formulary NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
Ruxolitinib 08.01.06 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Secukinumab 13.05.03 Non Formulary Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 13.05.03 Non Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Non Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Non Formulary NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Sofosbuvir with ledipasvir 05.03.03.02 Formulary NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Sofosbuvir with velpatasvir 05.03.03.02 Formulary NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Somatropin 06.05.01 Restricted Use NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Somatropin 06.05.01 Restricted Use NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Sorafenib 08.01.06 Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Sorafenib 08.01.06 Formulary NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sorafenib 08.01.06 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Sorafenib 08.01.06 Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sunitinib 08.01.06 Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib 08.01.06 Formulary NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib 08.01.06 Formulary NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Tacrolimus (topical) 13.05.03 Non Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03 Non Formulary NICE TA252: Hepatitis C (genotype 1) - telaprevir
Telbivudine 05.03.03.01 Non Formulary NICE TA154: Hepatitis B - telbivudine
Temozolomide 08.01.06 Non Formulary NICE TA23: Brain cancer - temozolomide
Temozolomide 08.01.06 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temsirolimus 08.01.06 Non Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Temsirolimus 08.01.06 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.06 Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disproxil 05.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA173
Tenofovir Disproxil 05.03.01 Formulary NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B
Teriflunomide 08.02.04 Non Formulary NICE TA303: Teriflunomide for relapsing remitting MS
Teriparatide 06.06.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thalidomide 08.02.04 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Ticagrelor 02.09 Restricted Use NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Ticagrelor 02.09 Restricted Use NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Tivozanib 08.01.06 Formulary NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Non Formulary NICE TA198: Rheumatoid arthritis - tocilizumab
Tocilizumab 10.01.03 Non Formulary NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
Tocilizumab 10.01.03 Non Formulary NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
Tofacitinib 10.01.03 Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tolvaptan 06.05.02 Restricted Use NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.06 Formulary NICE TA183: Topotecan for the treatment of relapsed small-cell lung cancer
Topotecan 08.01.06 Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Topotecan 08.01.06 Formulary NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
Topotecan 08.01.06 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.06 Non Formulary NICE TA222- ovarian cancer
Trabectedin 08.01.06 Non Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Tranexamic Acid 02.11 Formulary NICE guideline on heavy menstrual bleeding
Trastuzumab 08.01.06 Formulary NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
Trastuzumab 08.01.06 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Trastuzumab 08.01.06 Formulary NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Trastuzumab 08.01.06 Formulary NICE TA107: Breast cancer (early) - trastuzumab
Trastuzumab 08.01.06 Formulary NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Trastuzumab 08.01.06 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab emtansine 08.01.06 Formulary Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
Trastuzumab emtansine 08.01.06 Formulary Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trastuzumab emtansine 08.01.06 Formulary NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trifluridine with tipiracil 08.01.03 Formulary NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 01.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Non Formulary NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab 13.05.03 Non Formulary NICE TA313: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Non Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Valsartan with sacubitril 02.05.05.02 Formulary NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Varenicline 04.10.02 Non Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.06 Formulary NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
Vemurafenib 08.01.06 Non Formulary NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Vemurafenib 08.01.06 Non Formulary NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
Venetoclax 08.01.06 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Zanamivir inhalation 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Zanamivir inhalation 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zolpidem 04.01.01 Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
George Eliot Hospital